Nearly a quarter of overweight or obese adults in the U.S. have taken a GLP-1 — a class of weight loss drugs that includes Ozempic. But in some states, Medicaid doesn’t cover GLP-1s, though low-income Americans are more likely to be overweight or obese. In this episode: Who can access or afford this new medicine? Plus, striking hotel workers want higher pay and a return to pre-pandemic norms, the Federal Trade Commission is making it easier to cancel unwanted subscriptions, and the manufacturing sector is in a rut.
